🔎 Trials Near Me

Home › Scleroderma

Scleroderma clinical trials recruiting in the U.S.

33 studies for Scleroderma are recruiting participants at sites across the United States.

Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.

Cities with the most studies

By state

Recently updated studies

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06655155

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07497087

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717

FT839 in Autoimmune Diseases

RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 2, 2026 · NCT07800871

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542

Platform Clinical Study for Conquering Scleroderma

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

RecruitingPhase 2
Ages 8 to 60 · All sexes · Updated Aug 14, 2026 · NCT03630211

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Aug 7, 2026 · NCT06733935

A Study of AZD0120 in Autoimmune Diseases

RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07295847

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT07090226

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745

A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT06827977

Systemic Sclerosis DIet for GastrointESTinal Symptoms

Recruiting
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT07402226

US Zamto-cel Autoimmune Diseases

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT06708845

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

RecruitingObservational studyHealthy volunteers welcome
Up to age 90 · All sexes · Updated May 12, 2026 · NCT01808937

Intralesional Injection of STS in Treatment of Calcinosis

RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06672822

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT06434363

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 31, 2026 · NCT07047690

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 27, 2026 · NCT03844061

Open Label Treprostinil Raynaud's Study

RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 24, 2026 · NCT07112183

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.